Optical Express Group claims good patient outcomes

Article

Recent research by the Optical Express Group says it has revealed that of 32,000 clients surveyed following treatment in 2009, 89 per cent achieved 20/16 vision or better.

Recent research by the Optical Express Group says it has revealed that of 32,000 clients surveyed following treatment in 2009, 89 per cent achieved 20/16 vision or better. The business has also recently made a $12 million investment installing iFS 150 femtosecond laser systems in all its 44 treatment clinics in the UK.

Commenting on the trend towards better than 20/20 outcomes Dr Steve Schallhorn, Medical Director and Chair of the International Medical Advisory Board for Optical Express said: “What we have reported is that our highly skilled surgeons using the very latest advancements in LASIK technology, consistently results in most patients achieving better than 20/20 unaided vision. These outcomes are phenomenal and testament to the medical and surgical care provided by Optical Express. It is also setting a new world-wide standard for laser eye surgery procedure outcomes.

“From a very early stage, Optical Express decided to lead from the front by advancing the frontiers of laser eye surgery. Together with the greatest experience in ophthalmology, our International Medical Advisory Board is second to none and is driving up standards to deliver safe and effective eye surgery with high levels of patient satisfaction.

“We continue to have very high levels of satisfaction among our patients. This is evidenced through our growth over the last year, during a time of deep economic turmoil.”

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.